Abpro Holdings (ABP) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
3 Feb, 2026Executive summary
Annual meeting scheduled for September 18, 2025, to be held virtually, with voting on key proposals including director re-election, auditor ratification, and a reverse stock split.
Record date for voting is September 2, 2025, with 80,166,667 shares outstanding.
Proxy materials and annual report are available online for shareholder review.
Voting matters and shareholder proposals
Shareholders will vote on re-electing one Class I director (Ian McDonald) to serve until 2028.
Ratification of Wolf & Company, P.C. as independent auditor for fiscal year ending December 31, 2025.
Approval sought for a 1-for-10 reverse stock split to maintain Nasdaq listing and improve stock liquidity.
No cumulative voting or appraisal rights apply to these matters.
Board of directors and corporate governance
Board consists of five directors in three staggered classes; majority are independent per Nasdaq rules.
Committees include audit, compensation, and nominating/governance, all chaired by independent directors.
New non-employee director compensation policy includes cash retainers and equity awards.
Board and committee meetings were limited in 2024 due to recent business combination.
Latest events from Abpro Holdings
- Vote seeks to extend the business combination deadline, with redemption rights preserved.ABP
Proxy Filing3 Feb 2026 - Preclinical biotech with major funding needs registers large share and warrant resale, faces high dilution risk.ABP
Registration Filing3 Feb 2026 - Preclinical biotech with urgent capital needs registers up to 20.7M shares for resale under $50M SEPA.ABP
Registration Filing3 Feb 2026 - Shareholders will vote on extending the business combination deadline or face company liquidation.ABP
Proxy Filing3 Feb 2026 - Biotech registers major share resale and warrant exercise, faces funding and clinical risks.ABP
Registration Filing3 Feb 2026 - Biotech seeks $50M equity via SEPA amid going concern, dilution, and Nasdaq risks.ABP
Registration Filing3 Feb 2026 - Preclinical biotech seeks up to $50M via equity facility amid severe liquidity and delisting risks.ABP
Registration Filing3 Feb 2026 - Key votes include director re-election, auditor ratification, and a 1-for-10 reverse stock split.ABP
Proxy Filing3 Feb 2026 - Vote to approve up to $50M in stock issuance to Yorkville and potential meeting adjournment.ABP
Proxy Filing3 Feb 2026